GDF15 Emerges as a Master Regulator of Metabolic and Heart Disease
A comprehensive 2025 review maps how stress-cytokine GDF15 drives obesity, diabetes, heart failure, and aging—and how to target it therapeutically.
Summary
GDF15, a TGF-β superfamily stress cytokine, is elevated in obesity, diabetes, cardiovascular disease, cachexia, and aging. It acts primarily through its brainstem receptor GFRAL to suppress appetite and regulate energy balance. This 2025 review synthesizes the multilayered regulation of GDF15 expression—including transcription factors ATF4/CHOP, NRF2, p53, EGR1, and epigenetic silencer EZH2—and its interactions with metabolic hormones like FGF21, GLP-1, and leptin. Diet, exercise, metformin, and natural compounds all modulate GDF15 levels. Drug development targeting the GDF15/GFRAL axis, including monoclonal antibodies and fusion proteins, is actively advancing for obesity, heart failure, and cachexia.
Detailed Summary
GDF15 is a secreted, disulfide-linked homodimeric cytokine belonging to the TGF-β superfamily. Under physiological conditions it is expressed mainly in liver, kidney, and adipose tissue in mice, and most abundantly in the human placenta. During metabolic stress, inflammation, ischemia, and mitochondrial dysfunction, GDF15 is rapidly up-regulated across multiple tissues including heart, skeletal muscle, and liver, positioning it as a broad sentinel of cellular stress.
The review details a multilayered regulatory architecture governing GDF15. At the transcriptional level, the integrated stress response (ISR) drives eIF2α phosphorylation, enhancing ATF4 translation; ATF4 then dimerizes with CHOP to activate the GDF15 promoter. Additional transcriptional activators include p53 (via two functional promoter-binding sites), NRF2 (under oxidative stress), EGR1 (in a positive feedback loop with GDF15), ERRγ (during hepatic injury), and AMPK (responding to energy deprivation). PPARγ directly drives GDF15 transcription, while PPARβ/δ acts indirectly through AMPK and p53. Epigenetically, EZH2 silences GDF15 via H3K27me3 histone methylation. Post-transcriptionally, CNOT6L accelerates GDF15 mRNA decay via the CCR4-NOT deadenylase complex. Mitochondrial stress responses in myopathy and OxPhos dysfunction also potently induce GDF15 secretion.
GDF15 exerts its best-characterized metabolic effects through GFRAL, a brainstem-restricted receptor expressed exclusively in the area postrema and nucleus of the solitary tract. GFRAL lacks intrinsic intracellular signaling capacity but co-recruits the RET tyrosine kinase to activate downstream pathways (ERK, AKT, PLC). Genetic ablation of GFRAL completely abolishes GDF15-mediated anorexia and weight loss in diet-induced obese mice, confirming GFRAL as the essential central receptor. Peripheral receptors on myeloid cells and regulatory T cells have been identified, suggesting immunomodulatory roles beyond appetite control.
In cardiometabolic disease, elevated GDF15 correlates with adverse outcomes in obesity, type 2 diabetes, MASLD/MASH, heart failure, and atherosclerosis—reflecting both its role as a stress biomarker and a potential mediator. GDF15 interacts with key hormones: it synergizes with FGF21 during mitochondrial and nutritional stress, complements GLP-1 anorexigenic signaling, and is modulated by leptin and glucocorticoids. Lifestyle interventions including ketogenic diets, high-fat diets, and exercise alter circulating GDF15. Pharmacologically, metformin up-regulates GDF15 via AMPK/ATF3, contributing to its appetite-suppressing and weight-reducing effects. Natural compounds and multiple anti-hyperglycemic agents also induce GDF15.
Therapeutic development targeting the GDF15/GFRAL axis is advancing rapidly. Monoclonal antibodies neutralizing GDF15 (for cachexia and sarcopenia) and agonist fusion proteins or GDF15 mimetics (for obesity and heart failure) are in clinical trials. Key unresolved questions include the identity and significance of peripheral GDF15 receptors, contradictory findings on whether GDF15 is protective or pathogenic in specific cardiovascular contexts, and challenges in translating murine data—where GFRAL is restricted to the brainstem—to humans, where expression patterns may differ.
Key Findings
- GDF15 is regulated by a multilayer network including ATF4/CHOP, NRF2, p53, EGR1, AMPK, EZH2, and CNOT6L.
- GFRAL, expressed exclusively in the brainstem AP/NTS, is the essential receptor for GDF15's anorexigenic and weight-loss effects.
- Metformin raises GDF15 via AMPK/ATF3; GDF15 in turn enables full AMPK activation, forming a positive feedback loop.
- Peripheral GDF15 receptors on myeloid cells and regulatory T cells suggest immunometabolic roles beyond appetite regulation.
- Multiple drug modalities—monoclonal antibodies, fusion proteins, small molecules—targeting GDF15/GFRAL are in active clinical development.
Methodology
This is a comprehensive narrative review published in 2025 synthesizing 199 cited studies. It integrates animal model data, human clinical studies, single-cell transcriptomics, and pharmacological trial data. No original experimental data were generated by the authors.
Study Limitations
As a narrative review, it is subject to selection bias and does not perform meta-analysis. Species differences in GFRAL expression and contradictory findings across cardiometabolic disease contexts remain unresolved. Translation of mouse-derived mechanistic insights to human therapeutics remains a significant challenge.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.